Navigation Links
For embolism patients, clot-busting drug is worth risk
Date:2/21/2013

EAST LANSING, Mich. --- When doctors encounter a patient with a massive pulmonary embolism, they face a difficult choice: Is it wise to administer a drug that could save the patient's life, even though many people suffer life-threatening bleeding as a result?

Based on new findings published in the American Journal of Medicine, Michigan State University researchers are answering that question in no uncertain terms.

"The message to doctors is clear: Take the chance," said Paul D. Stein, a professor in MSU's Department of Osteopathic Medical Specialties. "It doesn't matter how old the patient is or what other chronic diseases the patient has. Administering the drug saves lives."

Pulmonary embolism is a potentially deadly blockage of arteries in the lungs caused by blood clots that travel from elsewhere in the body, usually the leg. Clot-dissolving drugs known as thrombolytic agents often can remove the blockage, but they also can cause brain hemorrhages and other major bleeding.

Stein found in an earlier study that only about a third of unstable pulmonary embolism patients -- those who are in shock or require a ventilator -- received thrombolytic therapy, even though the drugs decreased the risk of dying in the hospital from 50 percent to 15 percent.

"Doctors are smart," Stein said, "so why are only a third of patients getting the drug?"

To find out, Stein and Fadi Matta, MSU associate professor of osteopathic medical specialties, reviewed a national database of records from more than 1,000 hospitals. Their findings suggest that concern over the bleeding associated with thrombolytic therapy may keep doctors from giving the drug to patients who could be at higher risk.

In the study, only 20 percent of unstable patients with associated chronic conditions received the drug, compared to 80 percent of those without such conditions. Patients older than 60 also were less likely to receive the treatment.

Yet, even if patients had associated chronic conditions in addition to pulmonary embolism, the in-hospital death rate was 20 percent among those who received thrombolytic therapy, compared to 47 percent of those who did not get the clot-dissolving drug. The death rate also was lower among elderly patients who got the drug.

"Physicians apparently are afraid to give thrombolytic drugs to pulmonary embolism patients if they are elderly or have associated illnesses, and for good reason," Stein said. "Bleeding can be severe with such drugs, but the fact is, a lot more patients die if they don't get the drug than if they do."


'/>"/>

Contact: Andy McGlashen
andy.mcglashen@cabs.msu.edu
517-355-5158
Michigan State University
Source:Eurekalert

Related medicine news :

1. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Pulmonary Embolism or Other Serious Medical Issues to Call the Johnson Law Group-ASAP
2. US Drug Watchdog Now Urges Yaz Yasmin Birth Control Pill Users Who Suffered a Pulmonary Embolism or a Heart Attack to Call the Johnson Law Group Now-Before Time Runs Out
3. The US Drug Watchdog Now Warns Time Could Run Out to Get Women Yaz or Yasmin Birth Control Pill Users Identified if they Suffered a Heart Attack Stroke or a Embolism
4. Doctors fail to communicate impact of heart devices with patients, SLU study finds
5. For stroke patients, mechanical clot removal delivers no advantage over standard care
6. TraceLink Life Sciences Cloud Named Amazon AWS Grand Prize Winner for Protecting Patients, Enabling Health, Ensuring Track and Trace Compliance
7. Trauma patients, community say they support exception from informed consent research
8. New Association Created to Advocate for Medical Marijuana Patients, Dispensary Operators and Advocates
9. Doctors Often Miss Signs of Problem Drinking in Patients, Study Finds
10. Get New Patients, INC Releases New Infographic titled 'Are Negative Reviews Killing Your Medical Practice?"
11. Author of the Uplifting Cancer Survival Guide, The C Card and Me, Opens Online Shop with Inspiring Gifts for Cancer Patients, Survivors and Caregivers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... New Jersey (PRWEB) , ... February 27, 2017 , ... ... highest cancer rates, among all types and genders. And the need for advanced services ... by RWJ and its top-rated cancer care program, in collaboration with their non-profit partners ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards ... of International Social Design Awards. , The 7th A' Social Design Award ... and Institutions worldwide with realized projects and conceptual works. , The first phase ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... ... ... IndustryArchive.Org . is announcing a new way for B2B Sellers to ... pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase a ... that B2B buyers are controlling the sales process via the Internet and that ad ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  International Biophysics Corporation, a ... , today announced a 34% revenue growth in 2016 ... increase in unit sales.  This growth was fueled by its ... in addition to the expansion of its global sales of ... International Biophysics, CEO, "As we enter our 25 th ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
(Date:2/27/2017)... 27, 2017 Leading Countries, Technologies and Companies ... expected to grow at a CAGR of 8.9% from 2016-2021 and ... at a CAGR of 9.1% from 2016 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology: